Hepatotoxicity during TB treatment in people with HIV/AIDS related to NAT2 polymorphisms in Pernambuco, Northeast Brazil

Araujo-Mariz, Carolline; Militão de Albuquerque, Maria de Fátima P.; Lopes, Edmundo P.; Ximenes, Ricardo A. A.; Lacerda, Heloísa R.; Miranda-Filho, Demócrito B.; Lustosa-Martins, Brena B.; Pastor, André Filipe P.; Acioli-Santos, Bartolomeu.
Artículo en Inglés | ARCA | ID: arc-37516

Documentos relacionados

  1. [Post-tuberculosis lung disease: a neglected disease].
  2. The Immune Response to Mycobacterium tuberculosis in HIV-1-Coinfected Persons.
  3. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
  4. Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity.
  5. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
  6. Model-Informed Precision Dosing of Isoniazid: Parametric Population Pharmacokinetics Model Repository.
  7. Parametric population pharmacokinetics of isoniazid: a systematic review.
  8. Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
  9. Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil.
  10. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of TB Drugs for Children.